annunciato<\/a> di aver stipulato un accordo definitivo per acquisire Momenta Pharmaceuticals, Inc., societ\u00e0 che scopre e sviluppa nuove terapie per malattie immuno-mediate.<\/p>\nQuesta acquisizione offre a Janssen, societ\u00e0 farmaceutica di Johnson & Johnson, l’opportunit\u00e0 di ampliare la propria leadership nelle malattie immuno-mediate e guidare un’ulteriore crescita attraverso l’espansione nella malattie autoimmuni. La transazione includer\u00e0 pieni diritti globali per nipocalimab (M281), un anticorpo anti-FcRn clinicamente validato. Nipocalimab offre a Janssen l’opportunit\u00e0 di raggiungere un numero significativamente maggiore di pazienti perseguendo indicazioni in molte malattie autoimmuni con sostanziali esigenze mediche non soddisfatte in disturbi materno-fetali, disturbi neuro-infiammatori, reumatologia, dermatologia ed ematologia autoimmune. Nipocalimab ha recentemente ricevuto una designazione di malattia pediatrica rara da FDA.<\/p>\n
Nelle malattie autoimmuni gli anticorpi del corpo attaccano o danneggiano le sue stesse proteine, cellule e tessuti, spesso con conseguenze devastanti. Tali malattie includono la miastenia grave, le malattie emolitiche del feto e del neonato, l’anemia emolitica autoimmune e altre gravi malattie dermatologiche, reumatiche, neurologiche, ematologiche e renali. Si stima che circa il 2,5% della popolazione, ovvero circa 195 milioni di persone in tutto il mondo, soffra di qualche forma di malattia indotta da autoanticorpi, molte delle quali sono orfane e malattie rare.<\/p>\n
“Questa acquisizione amplia la leadership di Janssen nelle malattie autoimmuni e ci fornisce un importante catalizzatore per una crescita sostenuta. Le malattie causate da autoanticorpi sono spesso gravi e le attuali opzioni di trattamento dei pazienti sono insufficienti “, ha affermato Jennifer Taubert, Vicepresidente esecutivo, Presidente mondiale, Pharmaceuticals, Johnson & Johnson.” Siamo entusiasti dell’opportunit\u00e0 di far progredire ulteriormente l’assistenza ai pazienti combinando Le capacit\u00e0 di ricerca e sviluppo, commerciali e della catena di fornitura di livello mondiale di Johnson & Johnson con le persone di talento, la pipeline e la profonda esperienza di Momenta in questo importante settore “.<\/p>\n","protected":false},"excerpt":{"rendered":"
photo by National Cancer Institute Johnson & Johnson ha annunciato di aver stipulato un accordo definitivo per acquisire Momenta Pharmaceuticals, Inc., societ\u00e0 che scopre e sviluppa nuove terapie per malattie immuno-mediate. Questa acquisizione offre a Janssen, societ\u00e0 farmaceutica di Johnson & Johnson, l’opportunit\u00e0 di ampliare la propria leadership nelle malattie immuno-mediate e guidare un’ulteriore crescita attraverso l’espansione nella malattie autoimmuni. La transazione includer\u00e0 pieni diritti globali per nipocalimab (M281), un anticorpo anti-FcRn clinicamente validato. Nipocalimab offre a Janssen l’opportunit\u00e0…<\/p>\n","protected":false},"author":297440,"featured_media":1012214,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2852,2721,2857,2858],"class_list":["post-1012213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-acquisizione","tag-johnsonjohnson","tag-malattie-autoimmuni","tag-momenta-pharmaceuticals"],"acf":[],"yoast_head":"\n
Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by National Cancer Institute Johnson & Johnson ha annunciato di aver stipulato un accordo definitivo per acquisire Momenta Pharmaceuticals, Inc., societ\u00e0 che scopre e sviluppa nuove terapie per malattie immuno-mediate. Questa acquisizione offre a Janssen, societ\u00e0 farmaceutica di Johnson & Johnson, l’opportunit\u00e0 di ampliare la propria leadership nelle malattie immuno-mediate e guidare un’ulteriore crescita attraverso l’espansione nella malattie autoimmuni. La transazione includer\u00e0 pieni diritti globali per nipocalimab (M281), un anticorpo anti-FcRn clinicamente validato. Nipocalimab offre a Janssen l’opportunit\u00e0...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-25T06:55:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical\",\"datePublished\":\"2020-08-25T06:55:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/\"},\"wordCount\":314,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg\",\"keywords\":[\"acquisizione\",\"Johnson&Johnson\",\"malattie autoimmuni\",\"momenta pharmaceuticals\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/\",\"name\":\"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg\",\"datePublished\":\"2020-08-25T06:55:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg\",\"width\":2560,\"height\":1941},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/","og_locale":"en_US","og_type":"article","og_title":"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical - Frezza Partners","og_description":"photo by National Cancer Institute Johnson & Johnson ha annunciato di aver stipulato un accordo definitivo per acquisire Momenta Pharmaceuticals, Inc., societ\u00e0 che scopre e sviluppa nuove terapie per malattie immuno-mediate. Questa acquisizione offre a Janssen, societ\u00e0 farmaceutica di Johnson & Johnson, l’opportunit\u00e0 di ampliare la propria leadership nelle malattie immuno-mediate e guidare un’ulteriore crescita attraverso l’espansione nella malattie autoimmuni. La transazione includer\u00e0 pieni diritti globali per nipocalimab (M281), un anticorpo anti-FcRn clinicamente validato. Nipocalimab offre a Janssen l’opportunit\u00e0...","og_url":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/","og_site_name":"Frezza Partners","article_published_time":"2020-08-25T06:55:29+00:00","og_image":[{"width":2560,"height":1941,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical","datePublished":"2020-08-25T06:55:29+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/"},"wordCount":314,"image":{"@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg","keywords":["acquisizione","Johnson&Johnson","malattie autoimmuni","momenta pharmaceuticals"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/","url":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/","name":"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg","datePublished":"2020-08-25T06:55:29+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/national-cancer-institute-duNbFJRhaJQ-unsplash-scaled.jpg","width":2560,"height":1941},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/malattie-autoimmuni-johnson-johnson-acquisisce-momenta-pharmaceutical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Malattie autoimmuni: Johnson & Johnson acquisisce Momenta Pharmaceutical"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1012213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=1012213"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1012213\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/1012214"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=1012213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=1012213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=1012213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}